- Report
- October 2021
- 366 Pages
Global
From €3838EUR$4,000USD£3,319GBP
- Report
- April 2019
- 150 Pages
Global
From €7671EUR$7,995USD£6,633GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$3,908USD£3,132GBP
- Report
- November 2023
- 87 Pages
Global
From €3500EUR$3,908USD£3,132GBP
- Report
- November 2023
- 125 Pages
Global
From €3500EUR$3,908USD£3,132GBP
- Report
- July 2023
- 132 Pages
Global
From €912EUR$950USD£788GBP
- Report
- November 2021
- 1032 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- September 2022
- 141 Pages
Global
From €3425EUR$3,570USD£2,962GBP
- Report
- July 2021
- 235 Pages
Global
From €3562EUR$3,712USD£3,080GBP
- Report
- April 2020
- 338 Pages
Global
From €5152EUR$5,370USD£4,455GBP
- Report
- September 2023
- 140 Pages
Global
From €2877EUR$2,999USD£2,488GBP
- Book
- January 2024
- 496 Pages
- Book
- April 2015
- 264 Pages
- Book
- January 2023
- 200 Pages
- Book
- November 2011
Global
A diagnostic biomarker is a biological molecule or gene that is used to identify a particular disease or condition. It is used to diagnose, monitor, and predict the progression of a disease or condition. Diagnostic biomarkers are used to detect the presence of a disease or condition, to determine the severity of the disease or condition, and to monitor the effectiveness of treatments. Diagnostic biomarkers are used in a variety of medical fields, including oncology, neurology, cardiology, and infectious diseases.
Diagnostic biomarkers are typically identified through a variety of methods, including genetic sequencing, proteomics, and metabolomics. These methods allow for the identification of biomarkers that are specific to a particular disease or condition.
The diagnostic biomarker market is a rapidly growing field, with many companies developing and marketing diagnostic biomarkers. Companies in this market include Illumina, Thermo Fisher Scientific, Qiagen, Roche, and Agilent Technologies. Show Less Read more